Dr. McGregor on unmet needs in metastatic renal cell carcinoma
Bradley McGregor, MD, explains how despite major advances in metastatic renal cell carcinoma, there are still patients who do not respond or maintain their initial response to the novel treatment option. Therefore, McGregor, says there remains a need for novel treatment targets and therapies in this space. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
Mitochondrial metabolism may promote kidney cancer metastasis, new data show
August 14th 2024“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.
